secwatch.observer — SEC 8-K summary
======================================

Issuer:     Canton Strategic Holdings, Inc. (CNTN)
CIK:        0001861657
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0001493152-23-033591
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hillstream BioPharma changes name to Tharimmune, progress on acquiring TH104, plans Phase 1 trial in Q4
--------------------------------------------------------------------------------

- Name change to Tharimmune effective Sep 25, 2023; new ticker THAR on Nasdaq.
- Progressing towards acquiring clinical-stage asset TH104 with recently approved IND.
- Expects to close TH104 acquisition in Q4 2023 and launch/complete Phase 1 PK trial by year-end.
- TH104 targets chronic pruritis in primary biliary cholangitis; prior ex-US trials showed reliable bioavailability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1861657/000149315223033591/0001493152-23-033591-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1861657/000149315223033591/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033591

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer